NCT02440854 - Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

February 17, 2021

Study Completion Date

February 17, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

afatinib

Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.

Trial Locations (7)

12462

"Attikon University General Hospital of Attica", Haidari

54622

Bioclinic Thessaloniki, Thessaloniki

57001

Interbalkan Medical Center of Thessaloniki, Thessaloniki

57010

"General Hospital of Thessaloniki G. Papanikolaou", Thessaloniki

68100

University General Hospital of Evros, Alexandroupoli

71110

University General Hospital of Heraklion, Heraklion

115 27

"Chest Hospital of Athens Sotiria", Athens